Feed/Companies/Nouscom

Nouscom

As of 19 Oct 2026, Nouscom has raised $256.1M across 3 verified rounds on record (amounts in other currencies converted to USD), plus 1 round still being checked; latest: €120 million ($135 million) Series D led by M Ventures and Revelation Partners, announced 19 Oct 2026.

BUILT ON

A clinical-stage, cancer interception focused biotech developing next-generation immunotherapies

nouscom.comLinkedInBasel, SwitzerlandBiotechFounded 2015

LATEST ROUND

Series D

$135.0M · 2026-10-19

RAISED ON RECORD · USD

$256.1M

across 3 verified rounds · plus 1 round still being checked

INVESTORS

7 leads

SOURCES

Feed/Companies

Company

Every round on record, with the sources behind each and the investors on them.

BUILT ON

Rounds

[ 4 ]

Series D

$135.0M · 2026-10-19

led by M Ventures, Revelation Partners

Series C

$72.4M · 2023-11-14

[ HISTORY ]

led by Andera Partners, Bpifrance, M Ventures

Series B

$48.7M · 2017-11-06

[ HISTORY ]

led by Abingworth

Series A

$13.6M · 2016-05-17

[ HISTORY ]

led by LSP, Versant Ventures

Round	Amount	Announced	Lead	Buzz
Series D	$135.0M €120 million ($135 million)	2026-10-19	M Ventures, Revelation Partners	12 outlets. #2 in Trending
15 sources [ VERIFIED · CORRECTED ] read against 4 of 15 sources The company release states Angelini Industries, the European Investment Bank and Neva SGR as new investors; EU-Startups instead names Angelini Ventures and the EIB. The company release is preferred.

Company research

Fetched today

Founders

Riccardo Cortese · Co-Founder
He founded the genetic-vaccine company Okairos in 2007 and led it through its acquisition by GSK in 2013.
Elisa Scarselli · Chief Scientific Officer and Co-Founder
She joined Okairos in 2010 as Clinical Director and previously worked as a scientist and oncology group leader at IRBM/Merck, after research at the ZMBH in Heidelberg.
Alfredo Nicosia · Co-founder
He was previously a co-founder and Chief Scientific Officer of Okairos, and earlier held roles at IRBM, EMBL in Heidelberg, and the Sclavo Research Centre in Siena.
Antonella Folgori · Co-founder
Stefano Colloca · Co-founder
Cinzia Traboni

WHY IT MATTERS

Nouscom is targeting a major unmet need: the company says people with Lynch syndrome face high lifetime cancer risk while current management is limited to surveillance and surgery, and its NOUS-209 immunotherapy is designed to train the immune system to stop precancerous cells before tumors develop. Its €120 million Series D will fund a global registration-enabling trial, alongside long-term Phase 1b/2 data reporting that all evaluable carriers remained free of advanced adenomas and colorectal cancer at years 1 and 2.

Series C [ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it.	$72.4M €67.5 million ($72 million)	2023-11-14	Andera Partners, Bpifrance, M Ventures	No recent discussion
2 sources [ VERIFIED · CORRECTED ] read against 1 of 2 sources Removed 5AM Ventures, EQT Life Sciences, Versant Ventures · not in this round Leads added Andera Partners, Bpifrance, M Ventures · nouscom.com 5AM Ventures, EQT Life Sciences and Versant Ventures are identified as existing investors receiving continued support, not as participants in this round. [ BUILT WITH ]·[ SEARCH ]found by Firecrawl search·[ SCRAPE ]2 pages read: nouscom.com, walderwyss.com·[ JSON ]round read into a schema, with the sentence that states it·[ VERIFY ]correctedchecked against 1 of 2 sources·[ BRANDING ]logo and colour from the homepage·[ AGENT ]company research by the Firecrawl agent

Series B [ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it.	$48.7M €42 million	2017-11-06	Abingworth	No recent discussion
2 sources [ VERIFIED ] read against 2 sources [ BUILT WITH ]·[ SEARCH ]found by Firecrawl search·[ SCRAPE ]2 pages read: nouscom.com, prnewswire.com·[ JSON ]round read into a schema, with the sentence that states it·[ VERIFY ]confirmedchecked against 2 sources·[ BRANDING ]logo and colour from the homepage·[ AGENT ]company research by the Firecrawl agent

Series A [ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it.	$13.6M EUR 12 million	2016-05-17	LSP, Versant Ventures	No recent discussion
1 source [ DEVELOPING ] Developing: it holds up against its sources so far, and firms up as more reporting lands. read against 1 source Date 2017-05-17 → 2016-05-17 · nouscom.com The page is posted in 2017, but its announcement dateline states May 17, 2016; the dateline is used for the announcement date. No headquarters is stated. [ BUILT WITH ]·[ SEARCH ]found by Firecrawl search·[ SCRAPE ]1 page read: nouscom.com·[ JSON ]round read into a schema, with the sentence that states it·[ VERIFY ]correctedchecked against 1 source·[ BRANDING ]logo and colour from the homepage·[ AGENT ]company research by the Firecrawl agent

Nouscom

Company

Rounds

Sources

Profile

Investors

Nouscom

Rounds

Company research

Sources

Series D$135.0M2026-10-1915 sources

Series C$72.4M2023-11-142 sources

Series B$48.7M2017-11-062 sources

Series A$13.6M2016-05-171 source

Profile

Investors

Series D$135.0M2026-10-1914 investors

Series C$72.4M2023-11-147 investors

Series B$48.7M2017-11-064 investors

Series A$13.6M2016-05-172 investors